Creo 5.5
Payments companies reported to CMS as associated with Creo 5.5. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Creo 5.5, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Creo 5.5
These are the largest totals companies reported as associated with Creo 5.5. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Paul Kim | Charlotte, NC | Neurological Surgery | $18,548.31 |
| Walter Samora | Columbus, OH | Pediatric Orthopaedic Surgery | $18,524.67 |
| Damon Delbello | Hawthorne, NY | Orthopaedic Surgery | $17,299.81 |
| Virgilio Matheus | Orlando, FL | Neurological Surgery | $15,058.48 |
| Erkan Alci | Conway, SC | Orthopaedic Surgery of The Spine | $13,059.41 |
| Eugene Giddens | Myrtle Beach, SC | Neurological Surgery | $11,708.73 |
| David Skaggs | Los Angeles, CA | Orthopaedic Surgery | $11,028.29 |
| Joshua Ellwitz | Kalamazoo, MI | Orthopaedic Surgery of The Spine | $9,925.37 |
| Steven Vanni | Miami, FL | Neurological Surgery | $3,581.93 |
| David Xu | Columbus, OH | Neurological Surgery | $2,474.26 |
Prescribed Creo 5.5?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.